Healthcare Industry News: Pulse Oximetry
News Release - January 10, 2008
Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry TechnologyTeaching hospital sets the pace for healthcare in the Philadelphia suburbs with unique new capabilities enabled by Masimo SET and Masimo Rainbow SET technologies
IRVINE, Calif., Jan. 10 (HSMN NewsFeed) -- Abington Memorial Hospital and Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and Read-Through-Motion & Low Perfusion Pulse Oximetry, have announced the completion of Philadelphia-based Abington Memorial Hospital's system-wide conversion to Masimo SET Pulse Oximetry. The hospital performed an extensive and thorough evaluation of Masimo SET technology and cited clinical preference, patient safety and unique capabilities as key factors for the conversion.
Dr. Ara Moomjian, Chief of Neonatology at Abington Memorial Hospital, said, "When surveyed, Abington clinicians clearly preferred Masimo SET technology over other available Pulse Oximetry solutions and the superior performance of Masimo SET during multi-departmental evaluations only served to cement the decision."
Abington Memorial Hospital is a 570-bed regional teaching hospital in Abington, Pennsylvania. With more than 34,000 inpatient admissions and greater than 5,000 births annually, the hospital is a major regional referral center for cancer care, cardiac care, and surgery (including orthopaeadic surgery and neurosurgery) and maintains the only Level II trauma center in Montgomery County.
By making the conversion to Masimo, Abington Memorial Hospital joins other top hospitals in the United States -- including four of the top five -- as listed on the US News & World Report Honor Roll, which have all adopted Masimo SET as their primary Pulse Oximetry platform. Masimo SET is clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 readings even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. These studies demonstrate that Masimo SET delivers improvements in outcomes, safety and efficiency.
"After converting to Masimo SET, we noticed a significant decrease in false alarms," said Dr. Stephen Snyder, Neonatologist at Abington Memorial Hospital. "In the past, other monitors would falsely alarm in the presence of motion or low perfusion, which would prolong the patients' length of stay. Hospital protocols dictate that if a neonatal patient has a significant SpO2 alarm during the last 24 hours of their stay, they are required to be monitored longer before they can be discharged."
In addition to Abington Memorial Hospital's system-wide standardization to Masimo SET Pulse Oximetry, the conversion also allows hospital clinicians to utilize Masimo Rainbow SET technology. Masimo Rainbow SET is an upgradable noninvasive blood constituent monitoring platform that is capable of measuring additional blood constituents that previously required invasive procedures. Masimo Rainbow SET's first application is Pulse CO-Oximetry, the first and only technology platform capable of continuously and noninvasively measuring carboxyhemoglobin (SpCO) and methemoglobin (SpMet), in addition to oxyhemoglobin (SpO2), perfusion index (PI), pleth variability index (PVI) and pulse rate.
Joe E. Kiani, CEO of Masimo, stated, "Abington Memorial Hospital is a large and growing teaching hospital in the Philadelphia suburbs that is setting the pace for the next-generation of hospital physicians, specialists and clinical staff. This conversion is especially rewarding because they have chosen Masimo SET and Masimo Rainbow SET technologies to prepare their future generations of healthcare professionals. We are proud that Masimo SET is the Pulse Oximetry standard of care at work in Abington Memorial Hospital for today's patients and tomorrow's healthcare leaders."
Masimo (NASDAQ: MASI ) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion Pulse Oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased Pulse Oximetry's ability to detect life-threatening events. Masimo SET is clinically proven in more than 100 independent and objective studies to provide the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures carboxyhemoglobin (SpCO) and methemoglobin (SpMet), pleth variability index (PVI), in addition to oxyhemoglobin (SpO2), perfusion index (PI) and pulse rate, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.
Forward Looking Statements
This press release may include forward-looking statements. These forward-looking statements are based on current expectations about future events affecting us and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control, including: risks related to our assumption that Masimo SET and Masimo Rainbow SET will deliver a sufficient level of clinical improvement over alternative Pulse Oximetry and patient monitoring systems to allow for rapid adoption of the technology at hospitals, as well as other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the quarter ended September 29, 2007, filed with the Securities and Exchange Commission on November 1, 2007. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward- looking statements or the risk factors contained in our quarterly report on Form 10-Q for the quarter ended September 29, 2007, whether as a result of new information, future events or otherwise, except as may be required under the federal securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpCO, SpMet, PVI and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.